-
Betulinic Acid Limits Cyclophosphamide Liver Injury
2026-09-24
In a mouse model of cyclophosphamide-associated liver damage, betulinic acid reduced oxidative injury and mitochondrial apoptosis while shifting NRF2 and ERK–MAPK signaling in a protective direction. The study’s use of the MEK inhibitor PD98059 adds pharmacological evidence that ERK signaling contributes to the injury phenotype, although it does not establish a direct molecular target for betulinic acid.
-
OPP Reveals Translation Stress in B Cells
2026-09-23
O-propargyl-puromycin (OPP) can turn a brief labeling pulse into a readout of newly synthesized proteins. This article explains how to interpret that signal in B-cell mitochondrial stress studies—and what OPP can and cannot establish about antibody production.
-
Ziprasidone Augmentation in Anxious Depression
2026-09-23
This post-hoc moderator analysis examined whether anxious-depression status changed the effects of ziprasidone added to escitalopram after inadequate SSRI response. The findings support comparable antidepressant effects across anxiety subgroups, while providing little evidence for a clinically meaningful anxiolytic advantage in patients with higher anxiety.
-
GM 6001 (Galardin) for ECM Research
2026-09-22
GM 6001, also called Galardin, is a high-affinity broad-spectrum MMP inhibitor for testing extracellular matrix remodeling in neural, musculoskeletal, cancer, and vascular models. This practical guide connects matrix preservation with meniscal healing research, EGFR transactivation inhibition, and migration assays while emphasizing controls, solvent handling, and the limits of broad-spectrum pharmacology.
-
Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor
2026-09-22
The reference study used activity-based screening of approximately 6,000 compounds to identify merbromin as a selective inhibitor of the SARS-CoV-2 main protease, 3CLpro. Kinetic, binding, and docking analyses indicated mixed-type inhibition involving more than one binding site, providing a mechanistic starting point for inhibitor optimization while highlighting the limits of enzyme-only screening.
-
Alfuzosin HCl: Practical BPH Research Workflows
2026-09-21
Build reproducible Alfuzosin HCl workflows for spectral quantification, formulation release testing, and mechanistic studies of lower urinary tract smooth muscle relaxation. This guide translates a validated binary-mixture method into practical assay choices while addressing solubility, spectral overlap, storage, and data-quality risks.
-
Targeted mRNA Nanoparticles in Ischemic Stroke
2026-09-21
This ACS Nano study developed M2 microglia-targeting lipid nanoparticles carrying IL-10 mRNA to reduce postischemic neuroinflammation and repair blood–brain barrier injury. Its two-model design links targeted mRNA delivery with microglial polarization, neurological recovery, and a potentially extended preclinical treatment window.
-
Piezo1, Matrix Stiffness, and DRG Axon Regeneration
2026-09-20
This study identifies Piezo1 as a growth-cone mechanosensor that links extracellular matrix stiffness to Ca2+–CaMKII–FAK–actin signaling during dorsal root ganglion axon regrowth. Its bidirectional stiffness response and adult nerve-injury validation clarify how the mechanical microenvironment can either constrain or support peripheral nerve repair.
-
Acetylspiramycin: From Case Signal to Assay Design
2026-09-19
Acetylspiramycin and Spiramycin B offer a useful framework for connecting ribosomal pharmacology with compartment-aware infection research. This article interprets a refractory ocular toxoplasmosis case without overstating causality and converts its diagnostic lessons into practical assay decisions.
-
Oteseconazole: CYP51 Selectivity to Translation
2026-09-18
Oteseconazole (VT-1161) offers a focused translational case study in antifungal drug development: potent fungal CYP51 inhibition, activity across clinically relevant Candida species, retained activity against fluconazole-resistant isolates, and a more selective human P450 profile. This article connects mechanism, susceptibility testing, compound handling, transporter-mediated drug interaction strategy, and clinical positioning for researchers designing Candida-focused programs.
-
TRPV1/TRPA1 Control of TSLP in Nasal Epithelium
2026-09-18
The reference study identifies a calcium/NFAT pathway through which TRPV1 and TRPA1 activation increases TSLP production in nasal epithelial cells. Its experimental design links channel expression and calcium entry with cytokine transcription, protein secretion, and pathway inhibition, providing a useful framework for epithelial and sensory ion-channel research.
-
Bufalin Workflows for Cancer Cell Research
2026-09-17
Bufalin is a cardiotonic steroid that supports integrated apoptosis, migration, metabolism, and target-validation workflows rather than single-endpoint screening. This guide translates emerging hepatocellular carcinoma findings into practical assay design while connecting them with triple-negative breast cancer research and AP-1 biology.
-
Cinoxacin Workflows for Gram-Negative Research
2026-09-17
Cinoxacin provides a practical benchmark for Gram-negative susceptibility testing, urinary tract infection research, and antibiotic resistance studies. This workflow-focused guide connects its DNA synthesis inhibition, assay conditions, pharmacokinetic context, and troubleshooting considerations to reproducible bench experiments.
-
(S)-(+)-Dimethindene maleate: M2 Guide
2026-09-16
This practical guide explains how to use (S)-(+)-Dimethindene maleate as an M2 muscarinic receptor antagonist while accounting for its additional histamine H1 activity. It is suited to controlled receptor, autonomic, cardiovascular, and respiratory research workflows, but should not be treated as a clinical, diagnostic, or long-term solution-storage product.
-
Bufalin N1507: Reliable Cell-Assay Design
2026-09-16
Learn how Bufalin (SKU N1507) can improve the design and interpretation of cell viability, proliferation, and cytotoxicity experiments. This scenario-based guide connects solvent control, assay selection, STK33 evidence, and supplier evaluation for reproducible oncology research workflows.